Seminars in Oncology
Volume 34, Issue 6 , Pages 509-515 , December 2007

Randomized Adjuvant Therapy Trials in Melanoma: Surgical and Systemic

  • Alexander M.M. Eggermont

      Affiliations

    • Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
    • Corresponding Author InformationAddress correspondence to Alexander M.M. Eggermont, MD, PhD, Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands.
    • ,
  • Martin Gore

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, London, United Kingdom.

References 

  1. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–908
  2. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma (Comparison of excision with margins of 1 or 3 cm). N Engl J Med. 1988;318:1159-1156
  3. Cascinelli N: Update WHO-10 trial. WHO Program Meeting, Albany, NY, May 1995 (personal communication)
  4. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2004;97:1941–1946
  5. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495-150
  6. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm) (Results of a multi-institutional randomized surgical trial). Ann Surg. 1993;218:262–267
  7. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101–108
  8. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328
  9. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–766
  10. Ringborg U, Mansson Brahme E, et al. Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. In: 2005;Proceedings 6th World Melanoma Congress, Vancouver, Cananda, September 6–10, (abstr 28)
  11. Eggermont AMM, Gore M. European approach to adjuvant treatments of intermediate- and high-risk malignant melanoma. Semin Oncol. 2002;29:382–388
  12. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627–630
  13. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma (Preliminary results). Cancer. 1978;41:948–956
  14. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm) (Intergroup Melanoma Surgical Trial). Ann Surg Oncol. 2000;7:87–97
  15. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial (WHO Melanoma Programme). Lancet. 1998;351:793–796
  16. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  17. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  18. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: Long-term follow-up results. J Clin Oncol. 2003;21:1057–1065
  19. Doubrovsky A, De Wilt JH, Scolyer RA, et al. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol. 2004;11:829–836
  20. van Akkooi AC, de Wilt JH, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol (Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma). Eur J Cancer. 2006;42:372–380
  21. Morton DL, Thompson JF, Cochran AJ, et al. Multicenter Selective Lymphadenectomy Trial Group: Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma. J Clin Oncol. 2005;23(suppl):7500;(abstr)
  22. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  23. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: Are these nodes to be considered negative?. Ann Oncol. 2006;17:1578–1585
  24. van Akkooi AC, Bouwhuis M, de Wilt JHW, et al. Multivariable analysis of outcome after sentinel node biopsy or therapeutic lymph node dissection in melanoma patients. Br J Surg. 2007;94:1293–1299
  25. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004;30:686–691
  26. Kretschmer L, Beckmann I, Thoms KM, et al. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer. 2005;41:531–538
  27. van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:597–608
  28. Kang JC, Wanek LA, Essner R, et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol. 2005;23:4764–4770
  29. Pawlik TM, Ross MI, Thompson JF, et al. The risk of in-transit metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;36:4588–4590
  30. Eggermont AMM. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res. 2000;157:178–189
  31. Eggermont AMM. Reducing the need for sentinel node procedures by ultrasound examination of regional lymph nodes. Ann Surg Oncol. 2005;12:3–5
  32. Voit C, Kron M, Schafer G, et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2006;12:1682–1689
  33. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial (European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593). J Clin Oncol. 1998;9:2906–2912
  34. Grünhagen DJ, Brunstein F, Graveland WJ, et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg. 2004;240:939–947
  35. Grünhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12:597–608
  36. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol. 2002;20:4181–4190
  37. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058–2066
  38. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002;20:2067–2075
  39. Morton DL: Plenary presentation at Annual Meeting of the Society of Surgical Oncology, Atlanta GA, 2006
  40. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20:4549–4554
  41. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;5:1036–1044
  42. Eggermont AMM. Role of interferon in melanoma remains to be determined. Eur J Cancer. 2001;2147–2153
  43. Gogas H, Dafni U, Bafaloukos D, et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma. Proc Am Soc Clin Oncol. 2007;25:8505;(abstr)
  44. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet. 2005;366:1189–1196
  45. Eggermont AMM, Suciu S, Santinami M, et al. EORTC Melanoma Group EORTC 18991: Long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma: Final results of a randomized phase 3 trial. Proc Am Soc Clin Oncol. 2007;25:8504;(abstr)
  46. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818–1825
  47. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha provide a worth-while benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241–252
  48. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677
  49. Wheatley K, Ives N, Eggermont AM, et al. International Malignant Melanoma Collaborative Group Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of the randomised trials. Proc Am Soc Clin Oncol. 2007;25:8526;(abstr)
  50. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–718
  51. Bouwhuis M, Suciu S, Kruit W, et al. Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) vs observation (Obs). Proc Am Soc Clin Oncol. 2007;25:8507;(abstr)
  52. Stuckert JJ, Tarhini AA, Lee S, et al. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. Proc Am Soc Clin Oncol. 2007;25:8506;(abstr)
  53. Bouwhuis MG, Suciu S, Testor A, et al. Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation. Eur J Cancer. 2007;6(suppl 5):5
  54. Suciu S, Ghanem G, Kruit W, et al. Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC 18952 trial comparing interferon (IFN) vs observation. Proc Am Soc Clin Oncol. 2007;25:8518;(abstr)
  55. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?. Eur J Cancer. 2004;40:1825–1836

PII: S0093-7754(07)00179-0

doi: 10.1053/j.seminoncol.2007.09.003

Seminars in Oncology
Volume 34, Issue 6 , Pages 509-515 , December 2007

Article Tools